Good morning, all. Nice to you see on what looks to be a sunny day here on the Pharmalot corporate campus. The summer haze may have arrived, but we remain as busy as ever. So please join as we quaff our mandatory cup of stimulation and set out to learn about interesting developments. Hope your day goes well and drop us a line...
Dendreon Says Provenge Sales Topped $5M In July (Associated Press)
Ockham Strikes Deal For Patient Recruitment In Russia (Outsourcing Pharma)
Merck Says Hepatitis C Drug Meets Study Goals (Associated Press)
New Zealand Agrees To Improve Access To Drugs (PharmaTimes)
Genzyme & Isis Report Positive Cholesterol Drug Results (Associated Press)
Merck Downplays Arbitration With J&J (Seeking Alpha)
How Lilly Let Telaprevir Slip Away (Xconomy)
Pfizer Wins Ruling Denying Neurontin Class Action Lawsuit (Bloomberg News)
Health Canada Warns About GI Problem With Relistor (Winnipeg Free Press)
Apotex Sells 40 Products To AA Pharma (Toronto Star)
3 Comments
It seems that "unnamed" Merck executives are feeding SeekingAlpha some hogwash -- all while swearing to the SEC that the opposite is true.
Namaste
In addition, a New Jersey rights group has filed a federal suit, overnight, challenging the process used in forcing medicine on psychiatric patients in New Jersey -- that state stands alone in its deference to hospital boards.
In fact, prisoners in New Jersey have a more meaningful right to refuse meds than patients in private hospitals. Appalling.
Namaste
Interesting article on Telaprevir and Lilly.
I have mentioned before that I believe that based on the structures of these compounds that the idea for these drugs might have come from structure activity relationships of drug induced hepatotoxicity with Lilly's olanzapine (Zyprexa) and Schering-Plough's asenapine (Saphris).
Companies don't come up with ideas for new classes of compounds out of thin air. One method is they look at what compounds do and see if they can tweak it to get different effects at the same receptors.
Salmon